Literature DB >> 6832823

Experimental Campylobacter jejuni infection of adult mice.

M J Blaser, D J Duncan, G H Warren, W L Wang.   

Abstract

HA-ICR adult mice were studied to develop an animal model for Campylobacter jejuni enteritis in humans. Fecal and ileal cultures made by selective and nonselective methods showed that C. jejuni and related organisms are not bowel commensals. Intragastric feeding of 10(8) CFU of three different strains of C. jejuni produced infection in 100% of the animals, and infection rates were dose dependent. Pretreatment with antibiotics or opiates was not necessary to induce infection. Fresh isolates and strains passed on artificial media yielded similar infection rates. Infected mice did not show signs of illness, but transient bacteremia within 10 min of oral infection was observed in nearly 100%. The small intestine was the principal target organ, with epithelial inflammation seen 48 h after infection. Control mice of four species had undetectable serum immunoglobulin G antibody specific for the infecting strain, but infected mice showed peak titers at 1 week with rapid decline. Immunoglobulin M titers rose minimally, and immunoglobulin A titers did not rise. Infected mice uniformly became chronic asymptomatic excretors, shedding 10(4) to 10(6) CFU/g of feces; a minority were biliary carriers. Intestine carriage was most pronounced in the stomach and proximal small intestine. Because this experimental infection led to bacteremia, transient pathological changes, and immunoglobulin G titer rises, this model may be useful for evaluating the effects of prophylactic and therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832823      PMCID: PMC348033          DOI: 10.1128/iai.39.2.908-916.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Experimental Shigella infections. II. Characteristics of a fatal enteric infection in guinea pigs following the subcutaneous inoculation of carbon tetrachloride.

Authors:  S B FORMAL; G J DAMMIN; H SCHNEIDER; E H LABREC
Journal:  J Bacteriol       Date:  1959-12       Impact factor: 3.490

2.  Immunity to enteric infection in mice.

Authors:  F M Collins
Journal:  Infect Immun       Date:  1970-03       Impact factor: 3.441

Review 3.  Campylobacter enteritis.

Authors:  J P Butzler; M B Skirrow
Journal:  Clin Gastroenterol       Date:  1979-09

4.  [One case of vibrio fetus in Rattus norvegicus].

Authors:  P Pejtschev
Journal:  Zentralbl Veterinarmed B       Date:  1969-07

5.  A note on the isolation of spiral-shaped bacteria from the caecum of mice.

Authors:  S Roach; G W Tannock
Journal:  J Appl Bacteriol       Date:  1979-12

6.  Campylobacter enteritis presenting as an acute abdomen.

Authors:  D J Hay; L A Ganguli
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

7.  The isolation and nature of campylobacters (microaerophilic vibrios) from laboratory and wild rodents.

Authors:  D S Fernie; R W Park
Journal:  J Med Microbiol       Date:  1977-08       Impact factor: 2.472

8.  Experimental Campylobacter diarrhea in chickens.

Authors:  G M Ruiz-Palacios; E Escamilla; N Torres
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

9.  Intestinal colonization of neonatal animals by Campylobacter fetus subsp. jejuni.

Authors:  L H Field; J L Underwood; L M Pope; L J Berry
Journal:  Infect Immun       Date:  1981-09       Impact factor: 3.441

10.  Experimental infection of Rhesus monkeys with a human strain of Campylobacter jejuni.

Authors:  R B Fitzgeorge; A Baskerville; K P Lander
Journal:  J Hyg (Lond)       Date:  1981-06
View more
  32 in total

1.  New World monkey Aotus nancymae as a model for Campylobacter jejuni infection and immunity.

Authors:  Franca R Jones; Shahida Baqar; Alfonso Gozalo; Gladys Nunez; Nereyda Espinoza; Sharina M Reyes; Milagros Salazar; Rina Meza; Chad K Porter; Stephen E Walz
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Pathogenesis of Campylobacter fetus infections. Role of surface array proteins in virulence in a mouse model.

Authors:  Z Pei; M J Blaser
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

Review 3.  Campylobacter bacteremia: a rare and under-reported event?

Authors:  R Louwen; P van Baarlen; A H M van Vliet; A van Belkum; J P Hays; H P Endtz
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-03-17

4.  Diarrheal Mechanisms and the Role of Intestinal Barrier Dysfunction in Campylobacter Infections.

Authors:  Fábia Daniela Lobo de Sá; Jörg-Dieter Schulzke; Roland Bücker
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

5.  The polysaccharide capsule of Campylobacter jejuni modulates the host immune response.

Authors:  Alexander C Maue; Krystle L Mohawk; David K Giles; Frédéric Poly; Cheryl P Ewing; Yuening Jiao; Ginyoung Lee; Zuchao Ma; Mario A Monteiro; Christina L Hill; Jason S Ferderber; Chad K Porter; M Stephen Trent; Patricia Guerry
Journal:  Infect Immun       Date:  2012-12-17       Impact factor: 3.441

6.  Immune response of athymic and euthymic germfree mice to Campylobacter spp.

Authors:  J W Yrios; E Balish
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

7.  Pathogenesis of Campylobacter spp. in athymic and euthymic germfree mice.

Authors:  J W Yrios; E Balish
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

8.  Simple adult rabbit model for Campylobacter jejuni enteritis.

Authors:  M B Caldwell; R I Walker; S D Stewart; J E Rogers
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

9.  Colonization and infection of athymic and euthymic germfree mice by Campylobacter jejuni and Campylobacter fetus subsp. fetus.

Authors:  J W Yrios; E Balish
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

10.  Campylobacter jejuni outer membrane proteins are antigenic for humans.

Authors:  M J Blaser; J A Hopkins; M L Vasil
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.